# GS Biopharmaceutical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gs-biopharmaceutical

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Total disclosed funding: $14M
- Latest round: Series A (Nov 26, 2024)
- Investors on record: 3

## About

Established in 2018 and based in Shanghai, China, GS Biopharmaceutical operates as a biopharmaceutical company that mainly provides photosensitizers and related products. It has a R&D center in Shanghai. In November 2024, the company closed series A+ funding led by new investor Zhangjiang Venture.

The company's main business is the research, development and manufacturing of innovative photosensitizers and related products. The company's main product is an antitumor photosensitizer, "Sinoporphyrin sodium for injection". It also develops innovative photo or acoustic dynamic related devices for esophageal cancer, rectal cancer, and gliomas.

The company generates revenue by providing innovative photosensitizers and related products.

The company will use the series A+ funding to supplement and accelerate the research and development and commercialization of the company's core products in the field of photodynamic therapy.

## Funding rounds

- Series A, Nov 26, 2024 — Shanghai STVC Group, Zhangjiang Science & Technology Venture Capital
- Series A, Feb 28, 2024, $14M — Oriental Fortune Capital

## Investors

- Oriental Fortune Capital (https://capitalatlas.ai/funds/oriental-fortune-capital) — Series A
- Shanghai STVC Group (https://capitalatlas.ai/funds/shanghai-stvc-group) — Series A
- Zhangjiang Science & Technology Venture Capital (https://capitalatlas.ai/funds/zhangjiang-science-technology-venture-capital) — Series A